Abstract
Background As the COVID-19 pandemic continues to unfold, the infection fatality risk (IFR, i.e. risk of death among all infections including asymptomatic and mild infections) is crucial for gauging the burden of death due to COVID-19 in the coming months or years. Here we estimate the IFR of COVID-19 in New York City (NYC), the first epidemic center in the United States where the IFR remains unclear.
Methods We developed a meta-population network model-inference system to estimate underlying SARS-CoV-2 infection rates in NYC during the 2020 spring pandemic wave using case, mortality, and mobility data. Based on these estimates, we further estimated the IFR for all ages overall and for 5 age groups (i.e. <25, 25-44, 45-64, 65-74, and 75+ years) separately, during March 1 – June 6, 2020 (i.e., before NYC began its phased reopening).
Findings During March 1 – June 6, 2020, 205,639 laboratory-confirmed COVID-19 cases were diagnosed and 21,447 confirmed and probable COVID-19 deaths occurred among NYC residents. We estimated an overall IFR of 1.39% (95% Credible Interval: 1.04-1.77%) in NYC. Estimated IFR for the two oldest age groups (65-74 and 75+ years) was much higher than the younger age groups and about double estimates reported for elsewhere. In particular, weekly IFR was estimated as high as 6.7% for 65-74 year-olds and 19.1% for 75+ year-olds.
Interpretation These results are based on more complete ascertainment of COVID-19-associated deaths in NYC and thus likely more accurately reflect the true, higher burden of death due to COVID-19 than previously reported elsewhere.
Competing Interest Statement
JS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI and Merck. Other authors declare no conflict of interest.
Funding Statement
This study was supported by the National Institute of Allergy and Infectious Diseases (AI145883), the National Science Foundation Rapid Response Research Program (RAPID; 2027369), and the NYC DOHMH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was classified as public health surveillance and exempt from ethical review and informed consent by the Institutional Review Boards of both Columbia University and New York City Department of Health and Mental Hygiene.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
9
Blogs/Media
Author Videos